{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:41:05Z","timestamp":1792521665364,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018353","name":"European Crohn's and Colitis Organisation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017519","name":"Werner Otto Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012680","name":"Universit\u00e4tsklinikum Hamburg-Eppendorf","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["546185154"],"award-info":[{"award-number":["546185154"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EO2106"],"award-info":[{"award-number":["01EO2106"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.aohep.2025.102138","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:31:23Z","timestamp":1760221883000},"page":"102138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0036-2234","authenticated-orcid":false,"given":"Lorenz","family":"Kocheise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-5077","authenticated-orcid":false,"given":"Jan","family":"Kempski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-8701","authenticated-orcid":false,"given":"Yunhe","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-3061","authenticated-orcid":false,"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1551-3634","authenticated-orcid":false,"given":"Miriam","family":"Tomczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Gorgulho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsha","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Giehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-4255","authenticated-orcid":false,"given":"Constantin","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5777-1031","authenticated-orcid":false,"given":"Thorben W.","family":"Fruendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-3909","authenticated-orcid":false,"given":"Julian","family":"K\u00f6tt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Domanig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Giannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-479X","authenticated-orcid":false,"given":"J\u00f6ran","family":"L\u00fccke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Machicote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9710-1662","authenticated-orcid":false,"given":"Marianna","family":"Alunni-Fabbroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib Ben","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8331-9778","authenticated-orcid":false,"given":"Ignazio","family":"Piseddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelius","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.aohep.2025.102138_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.aohep.2025.102138_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"issue":"5","key":"10.1016\/j.aohep.2025.102138_bib0003","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1159\/000520095","article-title":"Advances in pharmacotherapy of hepatocellular carcinoma: a State-of-the-art review","volume":"40","author":"Reiter","year":"2022","journal-title":"Dig Dis"},{"issue":"20","key":"10.1016\/j.aohep.2025.102138_bib0004","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1016\/j.aohep.2025.102138_bib0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nature Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.102138_bib0006","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41571-023-00816-4","article-title":"Biomarkers for immunotherapy of hepatocellular carcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.aohep.2025.102138_bib0007","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1146\/annurev.bi.59.070190.004031","article-title":"Cytokines: coordinators of immune and inflammatory responses","volume":"59","author":"Arai","year":"1990","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"10.1016\/j.aohep.2025.102138_bib0008","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nature Rev Cancer"},{"issue":"6","key":"10.1016\/j.aohep.2025.102138_bib0009","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.aohep.2025.102138_bib0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"issue":"22","key":"10.1016\/j.aohep.2025.102138_bib0011","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.3390\/cells11223698","article-title":"The role of IL-6 in cancer cell invasiveness and metastasis\u2014Overview and therapeutic opportunities","volume":"11","author":"Ra\u0161kov\u00e1","year":"2022","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.aohep.2025.102138_bib0012","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumor Biology"},{"issue":"5","key":"10.1016\/j.aohep.2025.102138_bib0013","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.aohep.2025.102138_bib0014","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy","volume":"12","author":"Bent","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.aohep.2025.102138_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.aohep.2025.102138_bib0016","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 pathway in the liver: from physiopathology to therapy","volume":"64","author":"Schmidt-Arras","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102138_bib0017","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40164-024-00527-1","article-title":"The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases","volume":"13","author":"Wang","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"10.1016\/j.aohep.2025.102138_bib0018","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/biomedicines11102623","article-title":"Interleukin-6 in hepatocellular carcinoma: a dualistic point of view","volume":"11","author":"Nenu","year":"2023","journal-title":"Biomedicines"},{"issue":"16","key":"10.1016\/j.aohep.2025.102138_bib0019","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3748\/wjg.v12.i16.2563","article-title":"Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma","volume":"12","author":"Soresi","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2025.102138_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040883","article-title":"Interleukin-6 is a circulating prognostic biomarker for hepatocellular carcinoma patients treated with combined immunotherapy","volume":"14","author":"Myojin","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.aohep.2025.102138_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1329634","article-title":"Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma","volume":"15","author":"Du","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.aohep.2025.102138_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100672","article-title":"High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma","volume":"5","author":"Yang","year":"2023","journal-title":"JHEP Reports"},{"issue":"22","key":"10.1016\/j.aohep.2025.102138_bib0023","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/cncr.30237","article-title":"Comparison of hepatocellular carcinoma in Eastern versus Western populations","volume":"122","author":"Choo","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.aohep.2025.102138_bib0024","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.102138_bib0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.aohep.2025.102138_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2025.102138_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1578422","article-title":"Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC","volume":"16","author":"Cho","year":"2025","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.aohep.2025.102138_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16203543","article-title":"An early increase in IL-10 and TNF-alpha levels following Atezolizumab plus Bevacizumab treatment predicts survival in advanced hepatocellular carcinoma patients: a prospective cohort study","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.aohep.2025.102138_bib0029","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1111\/jgh.16672","article-title":"Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis","volume":"39","author":"Suzuki","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.102138_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14218\/JCTH.2015.00024","article-title":"IL-6 plays a crucial role in HBV infection","volume":"3","author":"Lan","year":"2015","journal-title":"J Clin Transl Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2025.102138_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092406","article-title":"Interleukin-6: a new marker of advanced-sarcopenic HCC cirrhotic patients","volume":"15","author":"Dalbeni","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.aohep.2025.102138_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007310","article-title":"Increased interleukin-6\/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer","volume":"11","author":"Naqash","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.aohep.2025.102138_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143080","article-title":"C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review","volume":"10","author":"Shrotriya","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.aohep.2025.102138_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"46","key":"10.1016\/j.aohep.2025.102138_bib0035","doi-asserted-by":"crossref","first-page":"75013","DOI":"10.18632\/oncotarget.12601","article-title":"Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer","volume":"7","author":"Thomsen","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.aohep.2025.102138_bib0036","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:49:58Z","timestamp":1780649398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125003631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1665268125003631"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102138","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102138"}}